SPLiNE's Planning and Proposals for the Stable Supply of Specialty Pharmaceuticals
First written in FY2017-Q1. 2 of 4 entries say "Restated". Latest entry: FY2022.
1 other company's latest entry also says "Restated".
- FY2022RestatedAnnual report
「In May 2021, SPLiNE Co., Ltd. (Chuo-ku, Tokyo), a wholly owned consolidated subsidiary of the Company, was entrusted with distribution services for IZCARGO® 10 mg intravenous infusion, a recombinant treatment for mucopolysaccharidosis type II for which JCR Pharmaceuticals Co., Ltd. (Ashiya, Hyogo) obtained marketing approval in March of the same year.」
SPLiNE continues to provide distribution services for specialty pharmaceuticals on a commissioned basis. - FY2022-Q1AdvancedAnnual report
「As part of this initiative, in May 2021, SPLiNE Co., Ltd. (Chuo-ku, Tokyo), a wholly owned consolidated subsidiary of the Company, was entrusted with distribution services for IZCARGO® 10 mg intravenous infusion, a recombinant treatment for mucopolysaccharidosis type II for which JCR Pharmaceuticals Co., Ltd. (Ashiya, Hyogo) obtained marketing approval in March of the same year.」
SPLiNE’s specialty-pharmaceutical stable-supply planning and proposal business advanced to the stage of being entrusted with distribution services for JCR Pharmaceuticals’ IZCARGO. - FY2017-Q3RestatedAnnual report
「In May, SPLiNE Co., Ltd. (Chuo-ku, Tokyo) was established to plan and propose solutions relating to the distribution of specialty pharmaceuticals, including orphan drugs.」
SPLiNE continues to provide planning and proposal services relating to the stable supply of specialty pharmaceuticals. - FY2017-Q1First statedAnnual report
「On 20 May of the same year, SPLiNE Co., Ltd. (Chuo-ku, Tokyo), which plans and proposes stable supply solutions for specialty pharmaceuticals, was established.」
SPLiNE Co., Ltd. was established on 20 May 2016, launching planning and proposal services for the stable supply of specialty pharmaceuticals as a new business.